Prof. Dr. Ahmet Dirican
@dr_dirican
Prof, MD, PhD Medical Oncology and Precision Medicine
Is pathology the first target of artificial intelligence? New data suggest it might be. AI has officially outperformed manual PD-L1 scoring. In a multicenter study published in ESMO Real World Data & Digital Oncology, the AI-powered DiaKwant algorithm delivered: 🔹 88% accuracy…
The FDA has granted traditional approval to tarlatamab-dlle for ES-SCLC. This DLL3-targeted bispecific T-cell engager extends OS to 13.6 months after platinum therapy (HR 0.60) — a survival gain we haven’t seen in years. This marks a breakthrough moment in small cell lung cancer:…
“Reading a cancer correctly from the very beginning determines the entire course of treatment. NGS makes this possible. We know the limitations of conventional tests. So the real question is this: 👉 Which other test can reveal the full genetic landscape of a tumor on its own?”…
Keynote-905 shows EVP/cystectomy supersedes surgery alone in cisplatin ineligible muscle invasive bladder cancer. How does ctDNA fit into this and how much EV is needed? Why does the survey arm perform poorly? The video below addresses this issue from our recent Uromigos meeting.…
Here is the #UromigosLive video for EVP in MIBC & IMVIGOR11 with ctDNA and atezolizumab 👉 youtu.be/lmH3HOW9caA
youtube.com
YouTube
UromigosLive 2025 - Peri-operative Therapy in Urothelial Cancer
Choosing the right database for your AI application is crucial. But how much does it impact RAG performance? Reinhard Sellmair's analysis provides a clear answer. towardsdatascience.com/graph-rag-vs-s…
Artificial intelligence is rapidly reshaping oncology—from diagnosis and treatment selection to clinical trial recruitment and patient management. Following the latest updates from ESMO AI & Digital Oncology 2025 through the ESMO Daily Reporter provides a real advantage in…
AI is rapidly taking its place in oncology. Patient selection for clinical trials is becoming more accurate and efficient. Early data presented at ESMO AI & Digital Oncology 2025 are promising. A large-language-model–based platform (MedgicalAI®) was able to identify eligible…
Tumor-agnostic therapies haven’t advanced as fast as expected over the past decade. We’re still not entirely “organ-independent.” There may be several reasons — many studies were small, single-arm trials, and most didn’t analyze additional genomic features such as resistance…
ASCO’s message is clear: AI is here to support clinicians, not replace them. Transparency, fairness, accountability, and human-centered application are now core principles for AI use in oncology. The ASCO Guidelines Assistant is already helping accelerate evidence-based clinical…
“A leader who taught us to trust science, reason, and ourselves. Respectfully remembering.” 🇹🇷 #MustafaKemalAtatürk
A lesson-worthy paper from Kurzrock and colleagues: Metastatic cancer is a moving target; keeping pace with its clonal evolution requires N-of-1, biomarker-driven combination strategies supported by serial tissue and liquid biopsies throughout treatment. #PrecisionOncology #Nof1…
Just out. Cracking the cancer resistance code. pubmed.ncbi.nlm.nih.gov/41175949/
Structured exercise after colon cancer treatment isn’t just “lifestyle.” The CHALLENGE trial showed a 28% reduction in recurrence and death with regular, guided exercise after adjuvant chemotherapy. Exercise is part of the treatment. Not a suggestion. A prescription. #OncoDaily…
Some things are changing. We can now detect cancer recurrence months earlier — sometimes long before it appears on imaging. This is where ctDNA adds a new layer to cancer follow-up: real-time tumor burden monitoring and earlier alerts than PET-CT alone. The CALLA and DUO-E…
Sometimes, less is more in genetic testing. New #ESMO recommendations suggest limiting breast cancer germline panels to only 7 genes: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BRIP1, and TP53 (for women under 40). ❌ CHEK2 & ATM: moderate penetrance, limited clinical value ❌…
One day, every cancer patient will have a digital assistant by their side. ESMO reminds us that artificial intelligence should not only process data — it must understand people. Large Language Models (LLMs) are becoming empathetic digital companions that listen, guide, and…
Is It Time for Digital Oncology Assistants in Cancer Care? #esmo2025 data show digital therapeutics can improve fatigue, QoL, and emotional wellbeing. But there’s still a long road ahead... 🔹 Personalization: Every patient is unique 🔹 Sustainability: Long-term engagement…
To the next generation of oncologists: Understanding liquid biopsy today means shaping tomorrow’s cancer care. Here’s a short moment from my session with oncology residents this week — where we explored how ctDNA is changing everything from adjuvant decisions to resistance…
Is it really safe to withhold adjuvant therapy in MRD-negative patients? IMvigor011 (#esmo2025 ) showed that ctDNA-negative bladder cancer patients had impressive outcomes — 12-month DFS 95%, OS 100%. But in ctDNA-positive patients, adjuvant atezolizumab made a real difference:…
United States Trends
- 1. #GMMTV2026 155K posts
- 2. Moe Odum N/A
- 3. #WWERaw 75.1K posts
- 4. Purdy 28.1K posts
- 5. Panthers 37.6K posts
- 6. Bryce 21.1K posts
- 7. Finch 14K posts
- 8. Keegan Murray 1,479 posts
- 9. Timberwolves 3,829 posts
- 10. Gonzaga 4,051 posts
- 11. 49ers 41.9K posts
- 12. Canales 13.3K posts
- 13. TOP CALL 9,021 posts
- 14. AI Alert 7,691 posts
- 15. Alan Dershowitz 2,537 posts
- 16. #FTTB 5,907 posts
- 17. Penta 10.6K posts
- 18. Niners 5,882 posts
- 19. Check Analyze 2,322 posts
- 20. Market Focus 4,620 posts
Something went wrong.
Something went wrong.